[go: up one dir, main page]

AR033337A1 - COMPLEJO DE ELETRIPTAN PROCEDIMIENTO PARA SU PREPARACION FORMULACIoN QUE LO CONTIENE Y USO EN LA PREPARACION DE MEDICAMENTOS - Google Patents

COMPLEJO DE ELETRIPTAN PROCEDIMIENTO PARA SU PREPARACION FORMULACIoN QUE LO CONTIENE Y USO EN LA PREPARACION DE MEDICAMENTOS

Info

Publication number
AR033337A1
AR033337A1 ARP000103223A ARP000103223A AR033337A1 AR 033337 A1 AR033337 A1 AR 033337A1 AR P000103223 A ARP000103223 A AR P000103223A AR P000103223 A ARP000103223 A AR P000103223A AR 033337 A1 AR033337 A1 AR 033337A1
Authority
AR
Argentina
Prior art keywords
preparation
eletriptan
medicines
formulation containing
complex procedure
Prior art date
Application number
ARP000103223A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR033337A1 publication Critical patent/AR033337A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Un complejo de eletriptán y derivado de ciclodextrina de formula 1 en al que R1a-g, R2a-g y R3a-g representan cada uno independientemente -OH o -O(CH2)4SO3H; con la condicion de que al menos uno de los R1a-g representa -O(CH2)4SO3H; o una sal farmacéuticamente aceptable del mismo. Este complejo es util en el tratamiento de la migrana, hipertension, emesis, depresion, ansiedad, trastornos alimenticios, obesidad, droga dependencia, cefalea, dolor, hemicrania paraxismal cronica y cefalea asociada con un trastorno vascular. Se describe también procedimiento para su preparacion, formulacion que contiene y su uso en la preparacion de medicamentos.
ARP000103223A 1999-06-29 2000-06-27 COMPLEJO DE ELETRIPTAN PROCEDIMIENTO PARA SU PREPARACION FORMULACIoN QUE LO CONTIENE Y USO EN LA PREPARACION DE MEDICAMENTOS AR033337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
AR033337A1 true AR033337A1 (es) 2003-12-17

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103223A AR033337A1 (es) 1999-06-29 2000-06-27 COMPLEJO DE ELETRIPTAN PROCEDIMIENTO PARA SU PREPARACION FORMULACIoN QUE LO CONTIENE Y USO EN LA PREPARACION DE MEDICAMENTOS

Country Status (44)

Country Link
US (2) US6713461B1 (es)
EP (1) EP1189640B1 (es)
JP (2) JP4454900B2 (es)
KR (1) KR20020015067A (es)
CN (1) CN1198654C (es)
AP (1) AP2001002369A0 (es)
AR (1) AR033337A1 (es)
AT (1) ATE290884T1 (es)
AU (1) AU770169B2 (es)
BG (1) BG106151A (es)
BR (1) BR0011845A (es)
CA (1) CA2376847C (es)
CO (1) CO5170494A1 (es)
CZ (1) CZ20014572A3 (es)
DE (1) DE60018744T2 (es)
DZ (1) DZ3320A1 (es)
EA (1) EA003908B1 (es)
EC (1) ECSP003551A (es)
EE (1) EE200100697A (es)
ES (1) ES2235879T3 (es)
GB (1) GB9915231D0 (es)
GE (1) GEP20043377B (es)
GT (1) GT200000102A (es)
HR (1) HRP20010951A2 (es)
HU (1) HUP0201629A3 (es)
IL (1) IL146341A0 (es)
IS (1) IS6163A (es)
MA (1) MA26801A1 (es)
MX (1) MXPA01013274A (es)
NO (1) NO20016430L (es)
NZ (1) NZ515235A (es)
OA (1) OA11964A (es)
PA (1) PA8496801A1 (es)
PE (1) PE20010346A1 (es)
PL (1) PL352902A1 (es)
SK (1) SK18932001A3 (es)
SV (1) SV2002000112A (es)
TN (1) TNSN00142A1 (es)
TR (1) TR200103827T2 (es)
UA (1) UA66932C2 (es)
UY (1) UY26224A1 (es)
WO (1) WO2001000243A1 (es)
YU (1) YU87501A (es)
ZA (1) ZA200110454B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
PL212428B1 (pl) * 2002-08-20 2012-09-28 Bristol Myers Squibb Co Kompleks aripiprazolu, preparat farmaceutyczny zawierajacy ten kompleks i jego zastosowanie
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
WO2019143925A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU212730B (en) 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
KR0179053B1 (ko) 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
ZA941544B (en) 1993-03-05 1994-10-31 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
CA2161684C (en) 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
UY25078A1 (es) 1997-07-03 2000-12-29 Pfizer Composiciones farmacéuticas que contienen eletriptan hemisulfato estabilizadas con cafeína
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
GT200000102A (es) 2001-12-14
CN1359303A (zh) 2002-07-17
ES2235879T3 (es) 2005-07-16
IL146341A0 (en) 2002-07-25
EP1189640B1 (en) 2005-03-16
AU770169B2 (en) 2004-02-12
DZ3320A1 (fr) 2001-01-04
TNSN00142A1 (fr) 2005-11-10
JP4454900B2 (ja) 2010-04-21
PA8496801A1 (es) 2002-02-21
EE200100697A (et) 2003-02-17
MA26801A1 (fr) 2004-12-20
PL352902A1 (en) 2003-09-22
CA2376847A1 (en) 2001-01-04
EA003908B1 (ru) 2003-10-30
GB9915231D0 (en) 1999-09-01
EP1189640A1 (en) 2002-03-27
KR20020015067A (ko) 2002-02-27
CZ20014572A3 (cs) 2002-08-14
HRP20010951A2 (en) 2005-04-30
OA11964A (en) 2006-04-17
US20040186076A1 (en) 2004-09-23
ATE290884T1 (de) 2005-04-15
HUP0201629A3 (en) 2003-11-28
NZ515235A (en) 2003-08-29
WO2001000243A1 (en) 2001-01-04
CN1198654C (zh) 2005-04-27
MXPA01013274A (es) 2002-06-04
UY26224A1 (es) 2001-01-31
JP2003503364A (ja) 2003-01-28
ZA200110454B (en) 2002-12-20
ECSP003551A (es) 2002-01-25
GEP20043377B (en) 2004-04-13
CA2376847C (en) 2007-09-25
SV2002000112A (es) 2002-02-05
NO20016430D0 (no) 2001-12-28
YU87501A (sh) 2004-05-12
BG106151A (en) 2002-05-31
US6713461B1 (en) 2004-03-30
CO5170494A1 (es) 2002-06-27
AU4774100A (en) 2001-01-31
UA66932C2 (en) 2004-06-15
HUP0201629A2 (hu) 2003-03-28
TR200103827T2 (tr) 2002-05-21
SK18932001A3 (sk) 2002-09-10
IS6163A (is) 2001-11-16
AP2001002369A0 (en) 2001-12-31
PE20010346A1 (es) 2001-03-26
EA200101106A1 (ru) 2002-06-27
DE60018744D1 (de) 2005-04-21
NO20016430L (no) 2002-02-26
JP2006257091A (ja) 2006-09-28
DE60018744T2 (de) 2006-05-18
BR0011845A (pt) 2002-03-05

Similar Documents

Publication Publication Date Title
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
AR033466A1 (es) Composicion farmaceutica estabilizada para administracion oral
NZ501419A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine for treating migraines, depression and eating disorders
CR9842A (es) Composiciones de celecoxib
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
ECSP941122A (es) Derivados de 5-arilindoles
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
PE20220764A1 (es) Conjugados de anticuerpo y farmaco
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
CL2009001278A1 (es) Compuestos biciclicos, derivados de 1-(4-pipridinil)-1,3-dihidro-2h-indol-2-ona sustituidos, analogos de nociceptina; composicion farmaceutica; y su uso en el tratamiento del dolor (div. sol. 2103-03)
DE60039921D1 (de) Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
AR033337A1 (es) COMPLEJO DE ELETRIPTAN PROCEDIMIENTO PARA SU PREPARACION FORMULACIoN QUE LO CONTIENE Y USO EN LA PREPARACION DE MEDICAMENTOS
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
FR2682041B1 (fr) Vaccin contre les infections a neisseria meningitidis.
BR0008182A (pt) Antagonistas do fator de necrose tumoral e seu uso em endometriose
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
KR940008677A (ko) 자기 면역 질환 치료약
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
GEP20043183B (en) Eletriptan Hydrobromide Monohydrate, Method for its Production and Use Thereof
RU2003105901A (ru) Противовоспалительное лекарственное средство
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
AR033477A1 (es) Composicion de iniciador radical
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
JPH10237071A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure